Mersana Therapeutics Inc (MRSN)
2.12
+0.10
(+4.95%)
USD |
NASDAQ |
Oct 04, 16:00
2.13
+0.01
(+0.47%)
After-Hours: 20:00
Mersana Therapeutics SG&A Expense (Annual): 59.54M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 59.54M |
| December 31, 2022 | 56.96M |
| December 31, 2021 | 36.89M |
| December 31, 2020 | 21.90M |
| December 31, 2019 | 17.28M |
| Date | Value |
|---|---|
| December 31, 2018 | 16.33M |
| December 31, 2017 | 10.46M |
| December 31, 2016 | 6.984M |
| December 31, 2015 | 5.347M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
17.28M
Minimum
2019
59.54M
Maximum
2023
38.52M
Average
36.89M
Median
2021
SG&A Expense (Annual) Benchmarks
| Chimerix Inc | 24.60M |
| Marinus Pharmaceuticals Inc | 61.15M |
| Jaguar Health Inc | 23.05M |
| Seres Therapeutics Inc | 87.74M |
| PDS Biotechnology Corp | 15.28M |